logo

For the Inventor, By the Inventor

La Chaux-de-Fonds, Switzerland

Ichnos Sciences Sa

Calculating rank
USPTO Granted Patents = 13

% Expired Patents = 23.1



Trademarks = 7

Forward Citations = 8

Loading Chart...
Loading Chart...

37 inventors (with patents filed for the assignee):

goldMedal Samuel Hou (7 out of 12 patents)

silverMedal Stanislas Blein (5 out of 15 patents)

bronzeMedal Rami Lissilaa (5 out of 7 patents)

4.  Romain Ollier (5 out of 6 patents)

5.  Jonathan Albert Back (4 out of 6 patents)

6.  Darko Skegro (4 out of 13 patents)

7.  Neelima Khairatkar-Joshi (2 out of 44 patents)

8.  Jeremy Loyau (2 out of 5 patents)

9.  Antoine Attinger (2 out of 4 patents)

10.  Sonia Letestu (2 out of 2 patents)

11.  Lionel Duarte (2 out of 2 patents)

12.  Filipa Abrantes (2 out of 2 patents)

13.  Laure Cahuzac (2 out of 2 patents)

14.  Thierry Monney (2 out of 5 patents)

15.  Nagarajan Muthukaman (1 out of 8 patents)


13 patents:

1. 12692314 - CD3/BCMA/CD38 Trispecific Antibodies (2026-07-28),
2. 12351602 - Methods of inactivating viral contaminants (2025-07-08),
3. 12281169 - Antibodies that bind to OX40 and their uses (2025-04-21),
4. 12006367 - CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production (2024-06-11),
5. 11970539 - Antibodies that bind to IL1RAP and uses thereof (2024-04-30),
6. 11891454 - Production of T cell retargeting hetero-dimeric immunoglobulins (2024-02-06),
7. 11884700 - Methods of inactivating viral contaminants (2024-01-30),
8. 11851502 - Production of T cell retargeting hetero-dimeric immunoglobulins (2023-12-26),
9. 11773166 - CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production (2023-10-03),
10. 11407839 - Antibodies that bind to OX40 and their uses (2022-08-09),
11. 10821100 - Triazolone compounds as mPGES-1 inhibitors (2020-11-03),
12. 10758517 - mPGES-1 inhibitor for the treatment of osteoarthritis pain (2020-09-01),
13. 10640564 - Antibodies that bind to CCR6 and their uses (2020-05-05),
Company Overview
Ichnos Sciences SA is a biopharmaceutical company based in La Chaux-de-Fonds, Switzerland, focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. The organization specializes in the design and advancement of monoclonal antibodies and other biologics, leveraging cutting-edge research to address unmet medical needs. With a commitment to scientific excellence, Ichnos aims to enhance patient outcomes through its robust pipeline of therapeutic candidates.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

13 Patents

#15 in La Chaux-de-Fonds

#878 in Switzerland

#45,104 in the World

La Chaux-de-Fonds, CH
La Chaux-de-Fonds, Switzerland

Ichnos Sciences Sa

Forward Citations = 8

37 inventors:

goldMedal Samuel Hou (7 out of 12 patents)

silverMedal Stanislas Blein (5 out of 15 patents)

bronzeMedal Rami Lissilaa (5 out of 7 patents)

4.  Romain Ollier (5 out of 6 patents)

5.  Jonathan Albert Back (4 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ichnos Sciences Sa. Retrieved from https://idiyas.com/company/ichnos-sciences-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…